Concurrent validation program to be necessary for Stillen and Joins generics by 2012

The Korea Food and Drug Administration says Korean firms producing a generic version of herbal medicines, such as Dong-A’s Stillen and SK Chemicals’ Joins, are obliged to perform concurrent validation program by 2012, adding that prospective validation should be necessary thereafter.

Under prospective validation program, potential risk factors of each process should be investigated so as to ...